Investors boost stakes in Illumina, which beat earnings estimates, driving its stock up.

Several institutional investors have increased their stakes in Illumina, Inc., a life sciences company. Vinva Investment Management Ltd bought 6,600 shares, while others like Rockefeller Capital Management and Maverick Capital Ltd adjusted their holdings. Illumina recently reported earnings of $1.14 per share, beating estimates by $0.26. Analysts have given positive ratings, with a consensus "Moderate Buy" and a target price of $164.00.

December 01, 2024
6 Articles